Inflammatix
PrivateLast Round
Series E
Sep 12, 2024
Total Funding Raised
$209.1M
Company Overview
Inflammatix is a molecular diagnostics company that develops rapid tests to measure immune responses and assist healthcare providers in diagnosing acute infections and sepsis using advanced machine-learning algorithms.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts, Hardware Sales, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Inflammatix Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Inflammatix Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E | Sep 12, 2024 | ||||
| Grant | Nov 18, 2021 | ||||
| Series D | Mar 16, 2021 | ||||
| Series C | Jan 10, 2020 | ||||
| Grant | Nov 14, 2019 |
Key People
Founding team and executive leadership
Inflammatix Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Think.Health | Series C, Series E, Series D |
| Grey Sky Venture Partners | Series C |
| Administration for Strategic Preparedness and Response | Grant |
| Khosla Ventures | Series D, Series C, Series E |
| Iberis Capital | Series E |
| OSF Ventures | Series D, Series E |
| Northpond Ventures | Series D, Series C, Series E |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 12, 2024
$57M round led by Khosla Ventures and Think.Health.
- Mar 16, 2021
$102M round led by D1 Capital Partners
Inflammatix Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Inflammatix's valuation, stock price, and market status.